

# $\gamma$ -Mangostin isolated from *Garcinia mangostana* L. suppresses inflammation and alleviates symptoms of osteoarthritis via modulating miR-124-3p/IL-6/NF- $\kappa$ B signaling

Yen-Shuo Chiu<sup>1,2,3,\*</sup>, Jia-Lin Wu<sup>4,5,\*</sup>, Chi-Tai Yeh<sup>6,7</sup>, Vijesh Kumar Yadav<sup>8,9</sup>, Hsu-Shan Huang<sup>10</sup>, Liang-Shun Wang<sup>11</sup>

<sup>1</sup>Department of Orthopedics, Shuang Ho Hospital, Taipei Medical University, Taipei 23561, Taiwan

<sup>2</sup>School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei 11031, Taiwan

<sup>3</sup>Research Center of Geriatric Nutrition, College of Nutrition, Taipei Medical University, Taipei 11031, Taiwan

<sup>4</sup>Department of Orthopedics and Traumatology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan

<sup>5</sup>Department of Orthopedics, Taipei Medical University Hospital, Taipei 11031, Taiwan

<sup>6</sup>Department of Medical Research and Education, Taipei Medical University - Shuang Ho Hospital, New Taipei 23561, Taiwan

<sup>7</sup>Department of Health Care Management, Yuanpei University of Medical Technology, Hsinchu 30015, Taiwan

<sup>8</sup>The Division of Translational Medicine, Graduate Institute of Biomedical Informatics, Taipei Medical University, Taipei 11031, Taiwan

<sup>9</sup>Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan

<sup>10</sup>Graduate Institute for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan

<sup>11</sup>Division of Thoracic Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei 23561, Taiwan

\*Equal contribution

**Correspondence to:** Hsu-Shan Huang, Liang-Shun Wang; **email:** [huanghs99@tmu.edu.tw](mailto:huanghs99@tmu.edu.tw); [wangls72269@yahoo.com.tw](mailto:wangls72269@yahoo.com.tw), [wangls8889@gmail.com](mailto:wangls8889@gmail.com)

**Keywords:** OA,  $\gamma$ -MS, inflammation, miR-124-3p

**Abbreviations:** OA: Osteoarthritis;  $\gamma$ -MS:  $\gamma$ -Mangostin; H & E: Hematoxylin-eosin

**Received:** September 21, 2019

**Accepted:** March 2, 2020

**Published:** April 16, 2020

**Copyright:** Chiu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## ABSTRACT

Osteoarthritis (OA) a disease associated with joints and become severe with age, due to softening, inflammation and degradation of cartilage in joints. The agents that can target OA is needed, specifically without any side effects. *Garcinia mangostana* L. (Mangosteen) a tropical fruit used to treat many skin and stomach associated ailments.  $\gamma$ -Mangostin ( $\gamma$ -MS) a key bioactive substance present in mangosteen. Here, we aimed to explore  $\gamma$ -MS potential in targeting the pro-inflammatory cytokine, factors and miRs in OA progression. Significantly,  $\gamma$ -MS suppresses the inflammatory cytokines (IL-6, TNF- $\alpha$ , and INF- $\gamma$ ) and factors (NF- $\kappa$ B, STAT3, and COX-2) which regulates/participate in the catabolic process of cartilage destruction. Result of Hematoxylin-eosin (H&E) staining of tissue sections of OA joints of  $\gamma$ -MS treated and non-treated mice confirm  $\gamma$ -MS improves the signs of injuries, and maintains the structural integrity of the articular cartilage (epiphyseal disk joints and bone marrow) and reduces inflammation. Mechanistically,  $\gamma$ -MS targets miR-98-5p and miR-124-3p which are found to suppress the expression IL-6 and NF- $\kappa$ B, respectively. But in OA these miRs are

inhibited, especially miR-124-3p which regulates not only NF- $\kappa$ B but also TNF- $\alpha$ , IL-6 and MMP7. With a further investigation underway,  $\gamma$ -MS represents an important source for treating and managing OA.

## INTRODUCTION

Osteoarthritis (OA) is a common form of the disease associated with joints in the body [1–4]. Mostly affecting the joints that have to bear the entire body weight, such as the knees, hips, hands, and spines [2, 3]. Common OA manifestations are associated with severe pain, stiffness, progressive destruction of cartilages and bones [5, 6]. But the cartilage degeneration mainly due to the biochemical and structural changes, or due to the imbalance between the catabolic and anabolic processes [7]. The etiology of OA includes various risk factors, such as joint injury, obesity, ageing, and heredity [8–11]. It has been estimated by 2020, OA will affect more than 50 million peoples in the United States. Studies suggest that the elevated level of pro-inflammatory factors, specifically interleukin (IL)-1 $\beta$ , IL-6, IL-8 and tumor necrosis factor-alpha (TNF- $\alpha$ ), and these compounds may induce lipid mediators such as cyclooxygenase 2 (COX-2) enzymes were observed in both OA mouse models and patients [12–15]. These inflammatory factors may activate the nuclear factor- $\kappa$ B (NF- $\kappa$ B) signaling pathway to stimulates the catabolic process and leads to extracellular matrix (ECM) breakdown via up-regulated expression of metalloproteinase (MMP's) [6, 12, 14]. Many cytokines levels are regulated by a DNA-binding molecule signal transducer and activator of transcription 3 (STAT3). Activation of STAT3 leads to increased pro-inflammatory cytokines and immune responses whereas the suppression of STAT3 improves OA [6, 16, 17]. The primary treatment of OA is mainly limited to analgesics, modified anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and glucocorticoids. However, these anti-inflammatory drugs have several adverse side effects and cannot completely alleviate the associated inflammation. Despite OA's high prevalence, there are only fewer studies concerning the molecular mechanism and genetic factors in the pathogenesis of OA has been explored [18–20]. MicroRNAs (miRNAs) are large family of small 21-25 nucleotide non-coding RNAs. Recent evidence indicates that these small molecules regulate both the catabolism and anabolism of bone and cartilage [21, 22]. The importance of miRNA expression has been studied earlier to identify specific miRNAs that are differentially expressed in OA and other diseases [23–25]. miR expression is seen to affect the expression of pro-inflammatory cytokine and contribute to the pathogenesis of OA [26].

Developing a drug which is very safe and has no side-effects is challenging, because of that use of traditional

and naturally available herbal medicines is getting more attention. *Garcinia mangostana* L. (Mangosteen) is a tropical fruit tree has been originally cultivated in Southeast Asia. It has long been consumed both as food and medicinal purposes, the dried pericarp of this fruits has been used particularly in treating ailments such as skin-related diseases, ulcers and diarrhea [27–29]. Mangosteen (MS) exudates a yellow resin is a rich source of xanthenes and many bioactive substances, includes  $\alpha$ -,  $\beta$ - and  $\gamma$ - Mangostin ( $\gamma$ -MS), garcinone B and E, along with mangostinone, tannins and flavonoids [30].

In this study, we aimed to examine the importance of mangosteen both *in vitro* and *in vivo*. Notably,  $\gamma$ -MS treatment suppresses the proinflammatory cytokines and factors, such as IL-6, NF- $\kappa$ B, STAT3, COX-2 TNF- $\alpha$ , and INF- $\gamma$  in OA mouse model via up-regulating the miR-124-3p.

## RESULTS

### Enzyme induced OA


We used papain-induced OA mouse model for evaluating the potential therapeutic effects of  $\gamma$ -mangostin. The overall experimental design was described in (Figure 1A and 1B). BALB/c mice were used for intra-articular injection of papain. After 40 days of papain treatment, serum mRNA levels of pro-inflammatory cytokines (IL-6, TNF- $\alpha$  and INF- $\gamma$ ) and the nuclear factor kappa-B (NF- $\kappa$ B) was found to be increased significantly in comparison to that of prior to OA induction. (Figure 1B). This finding served to mimic the biochemical and inflammatory responses during OA pathogenesis and the starting point for evaluating the effectiveness of our treatments with MS and  $\gamma$ -MS mice.

### $\gamma$ -MS inhibits inflammatory cytokines gene expression


To evaluate the ability of MS and  $\gamma$ -MS in inducing the anabolic process of tissue repair, and reduces the activity of the inflammatory cytokine in OA. The inflammatory cytokines are the compounds contributing to the pathogenesis of OA [6]. Result of real-time polymerase chain reactions shows that treatment of MS and  $\gamma$ -MS significantly reduces the relative level of IL-6, TNF- $\alpha$  and INF- $\gamma$  in comparison to control group (Figure 2A–2C). The expression level of NF- $\kappa$ B is also significantly reduced after the treatment (Figure 2D), NF- $\kappa$ B has been found to play an important role in the

**A****Intra-articular injection:**





Papain (2.5%), with 0.03M L-cysteine HCL)



Treatment	Dosage	Mode	Number	Frequency
control	vehicle	PO	N=3	5 times / week
MS	40mg/Kg	PO	N=3	5 times / week
γ-MS	40mg/Kg	PO	N=4	5 times / week

**B**

**Figure 1.** Establishment of mouse OA model (A) Schematic representation of the timeline of chemically induced OA and mangostin treatment regimen. The table describes the treatment conditions. (B) Real-time PCR analysis comparing serum mRNA levels of IL-6, TNF- $\alpha$  and NF- $\kappa$ B before (healthy, day 0) and post OA induction (day 40). It was clear that after OA induction (day-40), the mRNA level of IL-6, TNF- $\alpha$ , NF- $\kappa$ B, TNF- $\alpha$  and IFN- $\gamma$  were significantly higher than un-induced counterparts (day-2).



**Figure 2. Longitudinal qPCR analysis of serum inflammatory markers of OA.** (A–D) Relative ratio of mRNA expression of IL-6, TNF- $\alpha$ , IFN- $\gamma$  and NF- $\kappa$ B between OA control; MS and  $\gamma$ -MS treated mice and healthy control. Three-time points (black diamonds) at week 0, 3 and 7 represent the relative mRNA level from the healthy control mice. \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.005$ .

catabolic process and strongly associated with the development of OA [31].


### Therapeutic effect of $\gamma$ -MS

Although the mobility of OA patients appeared to be very limited and painful due to inflammation [32]. We confirmed that MS and  $\gamma$ -MS treatment improves the mobility significantly by subjecting treated and non-treated mice to an open field test to record their movement. Both the MS and  $\gamma$ -MS treated group mice moved more in comparison to the non-treated OA mice group (Figure 3A). Interestingly,  $\gamma$ -MS treated group shows better response ( $***p<0.001$ ) and improvement in walking than MS ( $**p<0.01$ ) and non-treated mice group. Over the period of treatment, the relative mRNA expression of IL-6, TNF- $\alpha$ , INF- $\gamma$  and NF- $\kappa$ B reduced significantly in  $\gamma$ -MS treated group (Figure 3B). To evaluate the effect of  $\gamma$ -MS on human synovial fibroblast cell line SW982 for checking the change in expression OA associated factors. We further analyzed the protein expression level of TNF- $\alpha$ , NF- $\kappa$ B, STAT3

and COX2 by using western blotting. The results show  $\gamma$ -MS treatment reduces the expression of TNF $\alpha$ , NF- $\kappa$ B, STAT3 and COX-2 in comparison to non-treated samples (Figure 3C).

### $\gamma$ -MS treatment-induced therapeutic effects were associated with an increased miR-124-3p level

A number of miRNAs have been studied earlier and found to be involved in the pathogenesis of OA [33, 34]. These miRNAs regulate the expression of both anabolic and catabolic associated genes, and the importance of epigenetic regulation of gene expression to the development of OA has been reported earlier [33, 34]. After stimulating the SW982 cells with IL-6, qRT-PCR analysis shows the significant decrease in the relative ratio of miR-24, miR-98-5p and miR-124-3p, whereas the most significant effect, is on miR-124-3p (Figure 4A), after  $\gamma$ -MS treatment this miRs significantly increased (Figure 4A). Predicted binding of these miRNA from online databases such as PITA [35], miRanda [36] and PicTar [37] shows IL-6 and NF- $\kappa$ B



**Figure 3.  $\gamma$ -MS treatment improved the mobility in OA mice and downregulated the expression of inflammatory markers.** (A) Total distance travelled (during the test period) comparison of OA control; MS and  $\gamma$ -MS treated OA mice, significant recovery of OA is observed  $\gamma$ -MS treated mice in comparison to control and MS treatment group; (B) Significant decrease in expression of IL-6, TNF- $\alpha$ , INF- $\gamma$  and NF $\kappa$ B were observed in  $\gamma$ -MS treatment group in comparison to the control group; (C) Western blot and bands quantified using densitometry analysis (ImageJ software). The treatment of  $\gamma$ -MS resulted in a markedly decrease in the expression of TNF- $\alpha$ , NF $\kappa$ B, STAT3, and COX2 as compared to the control group. The experiments were performed three times independently. Right panel represents the quantitative representation of 3 independent Western blot analyses. \* $P<0.05$ , \*\* $P<0.01$  and \*\*\* $P<0.001$ .

were targeted by miR-98-5p and miR-124-3p respectively (Figure 4B). Furthermore, a reporter assay for miR-124-3p was also demonstrated the direct binding of miR-124-3p with RELA (NF- $\kappa$ B) as described in Supplementary Figure 2. Inhibition of miR-124-3p led to an increase in the level of inflammatory markers, viz, NF- $\kappa$ B, TNF- $\alpha$ , IL-6 and MMP7 as observed both by qRT-PCR and western blotting (Figure 4C, 4D).

### Histopathological analyses in OA tissues after $\gamma$ -MS treatment


Next, we determined the efficacy of  $\gamma$ -MS on BALB/c OA mice through oral administration by evaluating the structural integrity of the articular cartilage injury. H & E staining of OA joint sections isolated from the mice revealed detectable degradation in the epiphyseal disk joints tissues, inflammation, degradation of cartilage and bone marrow necrosis in comparison to normal mice tissue (Figure 5A, 5B).  $\gamma$ -MS treated OA mice tissue sections shows signs of reparative resynthesis effect on epiphyseal disk joints tissues, intact bone marrow and inflammation is also reduced in comparison to non-treated OA control group mice (Figure 5C, 5D),

these sections were further evaluated and graded by two independent experienced pathologists, the grade score also suggests signs of healing and repair of tissues because of  $\gamma$ -MS treatment (Table 1). Safety of  $\gamma$ -MS treatment on normal tissue was also evaluated, there was no drug side effect in normal mice. There is no difference between the  $\gamma$ -MS treated and non-treated group tissue epiphyseal disk and bone marrow were intact (Supplementary Figure 1).

### DISCUSSION

In this study, we demonstrated the evidence both *in vivo* and *in vitro* that  $\gamma$ -MS administration suppressed the progression of OA in the chemically (papain) induced mouse model. Specifically, we showed that the  $\gamma$ -MS treatment delayed OA pathogenesis via suppressing chronic inflammation.

OA is characterized by both acute and chronic inflammations mostly in articular joints. In the late stage of OA, the destruction of the joints results in severe functional loss and disabilities in the patients. OA incidences have increased and become a major health issue for the ageing population [9, 38]. Complex




**Figure 4.  $\gamma$ -MS mediated effects were associated with increased miR-124-3p.** (A) qPCR analysis of different inflammation-associated miRs. SW982 cells were stimulated with IL-6 and showed a significantly decreased level of miR-24, miR-98-5p and miR-124-3p (the most responsive miR) while  $\gamma$ -MS treatment significantly increased these miRs. (B) Mir-Target prediction shows the 3'UTR sites of IL-6 and NF- $\kappa$ B respectively targeted by miR-98-5p and miR-124-3p. (C, D) qPCR and Western blot analysis (quantified band by densitometry analysis using ImageJ software) demonstrated that inhibitor of miR-124-3p led to an elevated level of inflammatory markers, TNF- $\alpha$ , IFN- $\gamma$ , IL-6 and MMP7 while the mimic molecule reduced the level. \*P<0.05, \*\*P<0.01 and \*\*\*P<0.001.

pathogenic mechanisms are involved in OA. Particularly, the articular synovial tissues are thought to play an important role, as both intra-articular cartilage lesions and secondary inflammatory lesions caused by synovial inflammations. That can facilitate the occurrence and advancement of OA, further severing the clinical symptoms [39, 40]. In addition, fibrosis of synovial tissues triggers a large number of inflammatory cells and pro-inflammatory cytokines, and associated factors which lead to the pathogenesis and progression of OA [41]. In healthy cartilage proper balance of anabolic and catabolic activities are important for the maintenance of cartilage tissue integrity and the repair of molecular damages. When this balance is compromised it leads to OA condition [42]. Tissue homeostasis is controlled by coordinated crosstalk among the factors that regulate this balance. Pro-inflammatory cytokines such as IL-6, TNF- $\alpha$ , INF- $\gamma$  involved in catabolic process in cartilage degradation and disease progression [43]. In addition, NF- $\kappa$ B signaling pathways have also been prominently

demonstrated in the pathogenesis of OA [44]. NF- $\kappa$ B is activated by inflammatory cytokines and acts in a positive feedback loop to stimulate the catabolic process by stimulating the inflammatory cytokines (ADAMTs) and enzymes MMPs that further leads in destruction of cartilage [44]. The observations that  $\gamma$ -MS treatment significantly reduced the expression of aforementioned inflammatory markers strongly suggests its potential as a disease-modifying agent for OA. Currently, non-steroidal anti-inflammatory drugs (NSAIDs) are used for pain management because of their ability to target COX-2, but it has unwanted gastrointestinal effects.

Administration of  $\gamma$ -MS to OA induced mice model showed a decrease in the level of expression of these pro-inflammatory cytokines and the transcriptional factor which further stimulates the pathogenicity and severity of OA (Figure 2A–2D). Also, the mobility of OA mice treated with  $\gamma$ -MS was measured (Figure 3A), and treatment group OA mice were able to walk further comparison to non-treated mice. Significant decrease in



**Figure 5. Comparative immunohistochemical analysis between the knee joints from control and  $\gamma$ -MS treatment groups.** The representative section of OA mice demonstrated signs of cartilage degradation and tissue injuries (epiphyseal disk and bone marrow) and inflammation in comparison to healthy normal counterparts (A, B).  $\gamma$ -MS treated mice showed a lower degree of cartilage destruction and more intact epiphyseal disk and bone marrow. as well as less inflamed in comparison to non-treated OA control group (C, D). H & E- stained images were taken at 40X (Bar = 100 $\mu$ M) and 200X magnification (Bar = 50 $\mu$ M).

**Table 1. Grading for histopathological changes in OA tissues after  $\gamma$ -MS treatment.**

Groups	Observer 1	Observer 2	Average grading (Score*)
Normal control	0	0	G 0
Osteoarthritis (OA)	3	3	Grade 3.0
OA + $\gamma$ -MS	1.5	2	Grade 1.5

\*The grading scores presented here represent the average score obtained from 2 separate pathologists.

### Histological grading scheme (McNulty et al., 2011)\*

Articular cartilage structure score (ACS)	
Grade (key feature)	Associated criteria (tissue reaction)
Grade 0	Articular surface morphology is intact and smooth
Grade 1-3	Fibrillation/clefts and loss of cartilage involving one by fourth or less of articular cartilage thickness
Grade 4-6	Fibrillation and/or clefts and/or loss of cartilage involving one half or less of articular cartilage thickness
Grade 7-9	Fibrillation and/or clefts and/or loss of cartilage involving more than one half of articular cartilage but less than full thickness
Grade 10-12	Fibrillation and/or clefts and/or loss of cartilage involving the full thickness of articular cartilage

\* McNulty MA, Loeser RF, Davey C, Callahan MF, Ferguson CM, Carlson CS. A Comprehensive Histological Assessment of Osteoarthritis Lesions in Mice. *Cartilage*. 2011; 2:354–63. <https://doi.org/10.1177/1947603511402665> PMID:26069594

serum mRNA levels of inflammatory cytokines and transcription factors were also observed for treatment group both by qRT-PCR and western blotting (Figure 3B–3C).

Our result also shows  $\gamma$ -MS targets and reduces the expression of NF- $\kappa$ B and STAT3 both of which are associated with catabolism and imbalances the body homeostasis. Expression of COX-2 (Figure 3C) was also targeted by  $\gamma$ -MS which is a major therapeutic target for pain management in the clinical settings. According to our data,  $\gamma$ -MS appeared to suppress a broader spectrum of inflammatory markers as compared to COX-2 inhibitors.

miRs are now becoming a great tool, that could play a key role in OA by regulating hundreds of genes that were important in homeostasis (catabolic and anabolic process) and OA pathology [45]. Especially, studies explained that miRNA-29 family targets NF- $\kappa$ B [46], miRNA-25 targets COX-2 [46], miRNA-149 and miRNA-98 targets TNF- $\alpha$  and IL-6 [23, 46] and they play an important part in OA. The qRT-PCR analysis shows  $\gamma$ -MS treatment significantly increased the miRs that were inhibited in IL-6 treated SW982 cells. For example, miR-24, miR-98-5p and miR-124-3p. Especially the expression of miR-98-5p and miR-124-3p which are predicted to target IL-6 and NF- $\kappa$ B from prediction software (Figure 4A, 4B). Importantly

inhibition of miR-124-3p resultant in the elevated level expression of inflammatory factors (NF- $\kappa$ B, TNF- $\alpha$ , IL-6 and MMP7) both at mRNA and protein level as compared to the control mimic treated group.

Intra-articular cartilage and inflammatory lesions caused by synovial inflammations can facilitate advancement and severing of OA [39, 40]. Our immunohistochemical analyses of the knee joint provided strong evidence that  $\gamma$ -MS treatment prevented the further destruction of the articular cartilage after injury or in case of OA. It was clear that  $\gamma$ -MS treated samples showed noticeable higher integrity of epiphyseal disk joints tissues, intact bone marrow and reduction in inflammation (Figure 5A–5D) in comparison to non-treated OA control group mice.

### CONCLUSIONS

This study provides evidence that  $\gamma$ -MS treatment both *in vitro* and *in vivo* significantly delayed pathogenesis of OA.  $\gamma$ -MS targets signaling molecules and regulators that contributes to inflammation and degradation of cartilages, which compromised the anabolic and catabolic balance of body homeostasis in OA. Hence, natural product ( $\gamma$ -MS) may function to manage OA and further development into the clinical settings is warranted.

## MATERIALS AND METHODS

### Preparation of mangostin and cell culture

Mangostin (MS) was purchased from Sigma Aldrich (catalogue no. PHL89247 purity is  $\geq 98\%$  (HPLC) while gamma ( $\gamma$ -MS) was provided by Genhealth Pharma, Taiwan Both MS and  $\gamma$ -MS were dissolved in dimethyl sulphoxide (DMSO) and stock of 100mmol/L prepared stored at  $-20^{\circ}\text{C}$ . Stock solutions were diluted before the experiment each time. The human synovial sarcoma cells SW982 obtained from the American Type Culture Collection (ATCC) and were cultured according to ATCC's recommended conditions. SW982 has been established as a common cell model as a surrogate for synovial fibroblasts for studying arthritis [47]. For IL-6 stimulation, SW982 cells were cultured with IL-6 (100ng/mL, 24h) to serve as an inflamed cell model, a protocol adapted from a previously established study [48]; subsequently, IL-6 induced SW982 cells were treated with  $\gamma$ -MS (5 $\mu\text{M}$ , 24h) and harvested for further analyses including qPCR and western blots.

### Animals

BALB/c mice, 6 weeks of age, were used as per the protocols approved by the Animal Use Protocol Taipei Medical University.

### Induction of osteoarthritis and drug administration

For the induction of OA in animals, 0.2ml of papain (P4762; SIGMA) and 0.1ml of cysteine were administered intra-articularly (2.5% papain and 0.03M L-cysteine HCL prepared in distilled water) accordingly [49, 50]. After the OA induction (please refer to Figure 1 for experimental design), the animals were divided into 4 groups, healthy controls (n=3), OA (vehicle control, n=3), MS (n=3), and  $\gamma$ -MS (n=4) treatment groups. MS and  $\gamma$ -MS were administrated orally (per os; p.o) at 40mg/kg dissolved in corn oil; doses five times a week.

### Hematoxylin-eosin (H&E) analysis

After 18 weeks, mice in the groups were humanely sacrificed by dislocating the neck, fresh knee cartilage tissues were collected and then preserved in 40g/L paraformaldehyde solution with phosphate buffer saline (PBS) for 22h. Fixed specimens were decalcified in 0.5 mol/L ethylenediaminetetraacetic acid (EDTA) solution for 30 days, and processed. Then a vertical incision was made to the articular cartilage with the scalpel blade. Specimens were then dried by automatic dehydrator and then embedded into paraffin, conventional histopathological slides were collected with 4 $\mu\text{M}$

sections. After dewaxing and dehydration of section, H&E staining was performed as previously described [51]. All the sections were carefully examined histologically, and the changes in cellular morphology were observed under a microscope at a magnification of X40 and X200.

### Real-time PCR

The total RNA was isolated and purified using TRIzol-based protocol (Life Technologies) according to the manufacturer's instructions. Hundred nano-grams of total RNA was reverse transcribed using QIAGEN One-step RT-PCR Kit (QIAGEN, Taiwan), and the PCR reaction was performed using a Rotor-Gene SYBR Green PCR Kit (400, QIAGEN, Taiwan).

The primers sequence for IL-6 were F: 5'- TAGCCGCC CCACACAGACAG-3'; R: 5'- GGGTTGGTGTTTAC GGTCGG-3'. The primer sequences for NF- $\kappa$ B were F: 5' GCGTACACATTCTGGGGAG -3'; R: 5'- CCGAA GCAGGAGCTATCAA -3'; the primer sequences for TNF- $\alpha$  were F: 5'- CCTGTAGCCCACGTCGTAGC-3'; R: 5'- AGCAATGACTCCAAAGTAGACC-3'; the primer sequences for IFN- $\gamma$  were F: 5'- CTCTGGCT GTTACTGCCAGG-3', R: 5'- CTCCACACTCTTTTG GATGCT-3'; the primer sequences for MMP-7 were F: 5'- TCCCGCGTCATAGAAATAATG-3', R: 5'- AGG AATGTCCCATACCCAAAG-3'. The primer sequences for the internal control RPLP0 were F: 5'-TGGTC ATCCAGCAGGTGTTTCGA-3', R: 5'-ACAGACACT GGCAACATTGCGG-3'.

The qRT-PCR for murine primer sequence given in Supplementary Table 1 and the microRNA primer that are used in this study were purchased from QIAGEN (QIAGEN, Taiwan), detailed catalogue number was enumerated in Supplementary Tables 1 and 2.

### Western blot

Total proteins of Human synovial sarcoma derived cell line (SW982) were extracted after treatment from different experiments were separated using the SDS-PAGE using Mini-Protean III system (Bio-Rad, Taiwan) and transferred onto PVDF membranes using Trans-Blot Turbo Transfer System (Bio-Rad, Taiwan). Membranes were incubated overnight at  $4^{\circ}\text{C}$  in following primary antibodies NF- $\kappa$ B (#6956S), TNF- $\alpha$  (#3707), IL-6 (#12912), MMP7 (Sc-8832), STAT3 (#4904), COX-2 (#4842) and  $\beta$ -actin (Sc-47778). Secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and ECL detection kit was used for the detection of the protein of interests. Images were captured and analyzed using UVP BioDoc-It system (Upland, CA, USA).



## Statistical analysis

All experiments were performed in triplicate. The statistical significance was calculated by unpaired two-tailed Student's t-test where more groups were involved, All the statistical analyses were performed using GraphPad Prism software where a p-value <0.05 was considered as statistically significant and was indicated with an asterisk.

## AUTHOR CONTRIBUTIONS

Conceptualization, Liang-Shun Wang; Data curation, Yen-Shuo Chiu; Jia-Lin Wu; Formal analysis, Yen-Shuo Chiu; Jia-Lin Wu, Chi-Tai Yeh and Vijesh Kumar Yadav; Funding acquisition, Liang-Shun Wang; Investigation, Liang-Shun Wang and Hsu-Shan Huang; Methodology, Yen-Shuo Chiu and Jia-Lin Wu; Project administration, Liang-Shun Wang Resources, Hsu-Shan Huang and Liang-Shun Wang; Supervision, Liang-Shun Wang and Hsu-Shan Huang; Validation, Yen-Shuo Chiu; Jia-Lin Wu and Chi-Tai Yeh; Visualization, Chi-Tai Yeh, Hsu-Shan Huang and Vijesh Kumar Yadav; Writing – original draft, Vijesh Kumar Yadav and Liang-Shun Wang; Writing – review and editing, Yen-Shuo Chiu, Vijesh Kumar Yadav and Jia-Lin Wu.

## ACKNOWLEDGEMENTS

We thank Mr Po-Yang Huang for his technical support in the establishment of a mouse model of osteoarthritis.

## CONFLICTS OF INTEREST

The authors have no known conflict of interest associated with the publication.

## FUNDING

JL Wu and SS Huang are funded by the research grant provided by Taipei Medical University and Taipei Medical University Hospital (Grant # 106TMU-TMUH-16).

## REFERENCES

1. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, Howell D, Kaplan D, Koopman W, et al, and Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. *Arthritis Rheum.* 1986; 29:1039–49. <https://doi.org/10.1002/art.1780290816> PMID:[3741515](https://pubmed.ncbi.nlm.nih.gov/3741515/)
2. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. *Pharmacotherapy: a pathophysiologic approach.* Ninth edition. McGraw-Hill Education, New York; 2014.
3. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch V, Wells G, Tugwell P, and American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care Res (Hoboken).* 2012; 64:465–74. <https://doi.org/10.1002/acr.21596> PMID:[22563589](https://pubmed.ncbi.nlm.nih.gov/22563589/)
4. Creamer P, Hochberg MC. Osteoarthritis. *Lancet.* 1997; 350:503–08. [https://doi.org/10.1016/S0140-6736\(97\)07226-7](https://doi.org/10.1016/S0140-6736(97)07226-7) PMID:[9274595](https://pubmed.ncbi.nlm.nih.gov/9274595/)
5. Toghraie FS, Chenari N, Gholipour MA, Faghih Z, Torabinejad S, Deghani S, Ghaderi A. Treatment of osteoarthritis with infrapatellar fat pad derived mesenchymal stem cells in Rabbit. *Knee.* 2011; 18:71–75. <https://doi.org/10.1016/j.knee.2010.03.001> PMID:[20591677](https://pubmed.ncbi.nlm.nih.gov/20591677/)
6. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. *Biorheology.* 2002; 39:237–46. PMID:[12082286](https://pubmed.ncbi.nlm.nih.gov/12082286/)
7. Mueller MB, Tuan RS. Anabolic/Catabolic balance in pathogenesis of osteoarthritis: identifying molecular targets. *PM R.* 2011 (Suppl 1); 3:S3–11. <https://doi.org/10.1016/j.pmrj.2011.05.009> PMID:[21703577](https://pubmed.ncbi.nlm.nih.gov/21703577/)
8. Chen D, Shen J, Zhao W, Wang T, Han L, Hamilton JL, Im HJ. Osteoarthritis: toward a comprehensive understanding of pathological mechanism. *Bone Res.* 2017; 5:16044. <https://doi.org/10.1038/boneres.2016.44> PMID:[28149655](https://pubmed.ncbi.nlm.nih.gov/28149655/)
9. Loeser RF. Aging and osteoarthritis: the role of chondrocyte senescence and aging changes in the cartilage matrix. *Osteoarthritis Cartilage.* 2009; 17:971–79. <https://doi.org/10.1016/j.joca.2009.03.002> PMID:[19303469](https://pubmed.ncbi.nlm.nih.gov/19303469/)
10. Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. *Arthritis Rheum.* 2012; 64:1697–707. <https://doi.org/10.1002/art.34453> PMID:[22392533](https://pubmed.ncbi.nlm.nih.gov/22392533/)
11. Goldring MB, Goldring SR. Osteoarthritis. *J Cell Physiol.* 2007; 213:626–34.


- <https://doi.org/10.1002/jcp.21258>  
PMID:17786965
12. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. *Nat Rev Rheumatol*. 2011; 7:33–42.  
<https://doi.org/10.1038/nrrheum.2010.196>  
PMID:21119608
  13. Shingu M, Miyauchi S, Nagai Y, Yasutake C, Horie K. The role of IL-4 and IL-6 in IL-1-dependent cartilage matrix degradation. *Br J Rheumatol*. 1995; 34:101–06.  
<https://doi.org/10.1093/rheumatology/34.2.101>  
PMID:7704454
  14. Martel-Pelletier J, Alaeddine N, Pelletier JP. Cytokines and their role in the pathophysiology of osteoarthritis. *Front Biosci*. 1999; 4:D694–703.  
<https://doi.org/10.2741/martel>  
PMID:10525480
  15. Wojdasiewicz P, Poniatowski ŁA, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. *Mediators Inflamm*. 2014; 2014:561459–561459.  
<https://doi.org/10.1155/2014/561459>  
PMID:24876674
  16. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. *Biochim Biophys Acta*. 2011; 1813:878–88.  
<https://doi.org/10.1016/j.bbamcr.2011.01.034>  
PMID:21296109
  17. Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, Dong C. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. *J Biol Chem*. 2007; 282:9358–63.  
<https://doi.org/10.1074/jbc.C600321200>  
PMID:17277312
  18. Hayashi S, Fujishiro T, Hashimoto S, Kanzaki N, Chinzei N, Kihara S, Takayama K, Matsumoto T, Nishida K, Kurosaka M, Kuroda R. p21 deficiency is susceptible to osteoarthritis through STAT3 phosphorylation. *Arthritis Res Ther*. 2015; 17:314.  
<https://doi.org/10.1186/s13075-015-0828-6>  
PMID:26546411
  19. Iliopoulos D, Malizos KN, Oikonomou P, Tsezou A. Integrative microRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks. *PLoS One*. 2008; 3:e3740.  
<https://doi.org/10.1371/journal.pone.0003740>  
PMID:19011694
  20. Kizawa H, Kou I, Iida A, Sudo A, Miyamoto Y, Fukuda A, Mabuchi A, Kotani A, Kawakami A, Yamamoto S, Uchida A, Nakamura K, Notoya K, et al. An aspartic acid repeat polymorphism in asporin inhibits chondrogenesis and increases susceptibility to osteoarthritis. *Nat Genet*. 2005; 37:138–44.  
<https://doi.org/10.1038/ng1496>  
PMID:15640800
  21. Miyamoto Y, Mabuchi A, Shi D, Kubo T, Takatori Y, Saito S, Fujioka M, Sudo A, Uchida A, Yamamoto S, Ozaki K, Takigawa M, Tanaka T, et al. A functional polymorphism in the 5' UTR of GDF5 is associated with susceptibility to osteoarthritis. *Nat Genet*. 2007; 39:529–33.  
<https://doi.org/10.1038/2005> PMID:17384641
  22. Goldring MB, Marcu KB. Cartilage homeostasis in health and rheumatic diseases. *Arthritis Res Ther*. 2009; 11:224.  
<https://doi.org/10.1186/ar2592>  
PMID:19519926
  23. Lotz MK, Kraus VB. New developments in osteoarthritis. Posttraumatic osteoarthritis: pathogenesis and pharmacological treatment options. *Arthritis Res Ther*. 2010; 12:211.  
<https://doi.org/10.1186/ar3046>  
PMID:20602810
  24. Yu XM, Meng HY, Yuan XL, Wang Y, Guo QY, Peng J, Wang AY, Lu SB. MicroRNAs' Involvement in Osteoarthritis and the Prospects for Treatments. *Evid Based Complement Alternat Med*. 2015; 2015:236179.  
<https://doi.org/10.1155/2015/236179>  
PMID:26587043
  25. Nugent M. MicroRNAs: exploring new horizons in osteoarthritis. *Osteoarthritis Cartilage*. 2016; 24:573–80.  
<https://doi.org/10.1016/j.joca.2015.10.018>  
PMID:26576510
  26. Marques-Rocha JL, Samblas M, Milagro FI, Bressan J, Martínez JA, Martí A. Noncoding RNAs, cytokines, and inflammation-related diseases. *FASEB J*. 2015; 29:3595–611.  
<https://doi.org/10.1096/fj.14-260323>  
PMID:26065857
  27. Wang Z, Chi X, Liu L, Wang Y, Mei X, Yang Y, Jia T. Long noncoding RNA maternally expressed gene 3 knockdown alleviates lipopolysaccharide-induced inflammatory injury by up-regulation of miR-203 in ATDC5 cells. *Biomed Pharmacother*. 2018; 100:240–49.  
<https://doi.org/10.1016/j.biopha.2018.02.018>  
PMID:29432995
  28. Chopra RN, Nayar SL, Chopra IC. Supplement to glossary of Indian medicinal plants. 1969. Publications & Information Directorate.
  29. Garnett M, Sturton S. *Garcinia Mangostana* in the

- treatment of amoebic dysentery. *Chin Med J.* 1932; 46:969–73.
30. Mahabusarakam W, Wiriyaichitra P, Taylor WC. Chemical constituents of *Garcinia mangostana*. *J Nat Prod.* 1987; 50:474–78.  
<https://doi.org/10.1021/np50051a021>
  31. Sato A, Fujiwara H, Oku H, Ishiguro K, Ohizumi Y.  $\alpha$ -mangostin induces  $\text{Ca}^{2+}$ -ATPase-dependent apoptosis via mitochondrial pathway in PC12 cells. *J Pharmacol Sci.* 2004; 95:33–40.  
<https://doi.org/10.1254/jphs.95.33>  
PMID:[15153648](https://pubmed.ncbi.nlm.nih.gov/15153648/)
  32. Khansai M, Phitak T, Klangjorhor J, Udomrak S, Fanhchaksai K, Pothacharoen P, Kongtawelert P. Effects of sesamin on primary human synovial fibroblasts and SW982 cell line induced by tumor necrosis factor- $\alpha$  as a synovitis-like model. *BMC Complement Altern Med.* 2017; 17:532.  
<https://doi.org/10.1186/s12906-017-2035-2>  
PMID:[29237438](https://pubmed.ncbi.nlm.nih.gov/29237438/)
  33. Hashizume M, Hayakawa N, Mihara M. IL-6 signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF- $\alpha$  and IL-17. *Rheumatology (Oxford).* 2008; 47:1635–40.  
<https://doi.org/10.1093/rheumatology/ken363>  
PMID:[18786965](https://pubmed.ncbi.nlm.nih.gov/18786965/)
  34. Udod VM, Storozhuk VT, Trofimenko SP, Shabash EG, Markelov SI. [Effect of the proteolytic enzyme papain on the body organs and systems of experimental animals]. *Farmakol Toksikol.* 1983; 46:95–98.  
PMID:[6852226](https://pubmed.ncbi.nlm.nih.gov/6852226/)
  35. Deng MW, Wei SJ, Yew TL, Lee PH, Yang TY, Chu HY, Hung SC. Cell Therapy With G-CSF-Mobilized Stem Cells in a Rat Osteoarthritis Model. *Cell Transplant.* 2015; 24:1085–96.  
<https://doi.org/10.3727/096368914X680091>  
PMID:[24667079](https://pubmed.ncbi.nlm.nih.gov/24667079/)
  36. Zhang W, Cheng P, Hu W, Yin W, Guo F, Chen A, Huang H. Inhibition of microRNA-384-5p alleviates osteoarthritis through its effects on inhibiting apoptosis of cartilage cells via the NF- $\kappa$ B signaling pathway by targeting SOX9. *Cancer Gene Ther.* 2018; 25:326–38.  
<https://doi.org/10.1038/s41417-018-0029-y>  
PMID:[30057417](https://pubmed.ncbi.nlm.nih.gov/30057417/)
  37. Murahashi Y, Yano F, Kobayashi H, Makii Y, Iba K, Yamashita T, Tanaka S, Saito T. Intra-articular administration of I $\kappa$ B $\alpha$  kinase inhibitor suppresses mouse knee osteoarthritis via downregulation of the NF- $\kappa$ B/HIF-2 $\alpha$  axis. *Sci Rep.* 2018; 8:16475.  
<https://doi.org/10.1038/s41598-018-34830-9>  
PMID:[30405206](https://pubmed.ncbi.nlm.nih.gov/30405206/)
  38. Scanzello CR, McKeon B, Swaim BH, DiCarlo E, Asomugha EU, Kanda V, Nair A, Lee DM, Richmond JC, Katz JN, Crow MK, Goldring SR. Synovial inflammation in patients undergoing arthroscopic meniscectomy: molecular characterization and relationship to symptoms. *Arthritis Rheum.* 2011; 63:391–400.  
<https://doi.org/10.1002/art.30137>  
PMID:[21279996](https://pubmed.ncbi.nlm.nih.gov/21279996/)
  39. Rodova M, Lu Q, Li Y, Woodbury BG, Crist JD, Gardner BM, Yost JG, Zhong XB, Anderson HC, Wang J. Nfat1 regulates adult articular chondrocyte function through its age-dependent expression mediated by epigenetic histone methylation. *J Bone Miner Res.* 2011; 26:1974–86.  
<https://doi.org/10.1002/jbmr.397>  
PMID:[21452283](https://pubmed.ncbi.nlm.nih.gov/21452283/)
  40. Zhang M, Lu Q, Egan B, Zhong XB, Brandt K, Wang J. Epigenetically mediated spontaneous reduction of NFAT1 expression causes imbalanced metabolic activities of articular chondrocytes in aged mice. *Osteoarthritis Cartilage.* 2016; 24:1274–83.  
<https://doi.org/10.1016/j.joca.2016.02.003>  
PMID:[26903200](https://pubmed.ncbi.nlm.nih.gov/26903200/)
  41. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. *Nat Genet.* 2007; 39:1278–84.  
<https://doi.org/10.1038/ng2135> PMID:[17893677](https://pubmed.ncbi.nlm.nih.gov/17893677/)
  42. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. *PLoS Biol.* 2004; 2:e363–363.  
<https://doi.org/10.1371/journal.pbio.0020363>  
PMID:[15502875](https://pubmed.ncbi.nlm.nih.gov/15502875/)
  43. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. Combinatorial microRNA target predictions. *Nat Genet.* 2005; 37:495–500.  
<https://doi.org/10.1038/ng1536>  
PMID:[15806104](https://pubmed.ncbi.nlm.nih.gov/15806104/)
  44. Greene MA, Loeser RF. Aging-related inflammation in osteoarthritis. *Osteoarthritis Cartilage.* 2015; 23:1966–71.  
<https://doi.org/10.1016/j.joca.2015.01.008>  
PMID:[26521742](https://pubmed.ncbi.nlm.nih.gov/26521742/)
  45. Kumagai K, Kubo M, Imai S, Toyoda F, Maeda T, Okumura N, Matsuura H, Matsusue Y. The COX-2 selective blocker etodolac inhibits TNF $\alpha$ -induced apoptosis in isolated rabbit articular chondrocytes. *Int J Mol Sci.* 2013; 14:19705–15.  
<https://doi.org/10.3390/ijms141019705>  
PMID:[24084720](https://pubmed.ncbi.nlm.nih.gov/24084720/)
  46. Scanzello CR, Goldring SR. The role of synovitis in


- osteoarthritis pathogenesis. *Bone*. 2012; 51:249–57.  
<https://doi.org/10.1016/j.bone.2012.02.012>  
PMID:[22387238](https://pubmed.ncbi.nlm.nih.gov/22387238/)
47. Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. *Arthritis Res Ther*. 2017; 19:18–18.  
<https://doi.org/10.1186/s13075-017-1229-9>  
PMID:[28148295](https://pubmed.ncbi.nlm.nih.gov/28148295/)
48. Maldonado M, Nam J. The role of changes in extracellular matrix of cartilage in the presence of inflammation on the pathology of osteoarthritis. *Biomed Res Int*. 2013; 2013:284873–284873.  
<https://doi.org/10.1155/2013/284873>  
PMID:[24069595](https://pubmed.ncbi.nlm.nih.gov/24069595/)
49. Schuerwegh AJ, Dombrecht EJ, Stevens WJ, Van Offel JF, Bridts CH, De Clerck LS. Influence of pro-inflammatory (IL-1 $\alpha$  IL-6, TNF- $\alpha$  IFN- $\gamma$ ) and anti-inflammatory (IL-4) cytokines on chondrocyte function. *Osteoarthritis Cartilage*. 2003; 11:681–87.  
[https://doi.org/10.1016/S1063-4584\(03\)00156-0](https://doi.org/10.1016/S1063-4584(03)00156-0)  
PMID:[12954239](https://pubmed.ncbi.nlm.nih.gov/12954239/)
50. Rigoglou S, Papavassiliou AG. The NF- $\kappa$ B signalling pathway in osteoarthritis. *Int J Biochem Cell Biol*. 2013; 45:2580–84.  
<https://doi.org/10.1016/j.biocel.2013.08.018>  
PMID:[24004831](https://pubmed.ncbi.nlm.nih.gov/24004831/)
51. Mirzamohammadi F, Papaioannou G, Kobayashi T. MicroRNAs in cartilage development, homeostasis, and disease. *Curr Osteoporos Rep*. 2014; 12:410–19.  
<https://doi.org/10.1007/s11914-014-0229-9>  
PMID:[25091054](https://pubmed.ncbi.nlm.nih.gov/25091054/)

SUPPLEMENTARY MATERIALS

Supplementary Figures



**Supplementary Figure 1. H & E staining of normal knee control.** (A–D)  $\gamma$ -MS treatment is also not showing any drug side effect in normal mice. There is no difference between the treated and non-treated group tissue (epiphyseal disk and bone marrow). H & E- stained images were taken at 40X (Bar = 100 $\mu$ M) and 200X magnification (Bar = 50 $\mu$ M).



**Supplementary Figure 2. Luciferase reporter assay.** The insert demonstrates the sequences of 3'UTR of RELA (WT, wild type) and mutant (MUT, red letters, altered nucleotides) used for demonstrating the direct binding of miR-124-3p with RELA (NF- $\kappa$ B). The luciferase activity was significantly lower when SW982 cells were transfected with RELA (WT) and miR-124-3p, while no difference was observed in both vector control and RELA (MUT). \*\*\*P<0.001; NS, not significant

## Supplementary Tables

**Supplementary Table 1. Murine primer sequence.**

<b>miRNA</b>	<b>Murine Primer Sequences</b>
Mouse TNF- $\alpha$ -F	TCTCATGCACCACCATCAAGGACT
Mouse TNF- $\alpha$ -R	TGACCACTCTCCCTTTGCAGAACT
Mouse NF- $\kappa$ B -F	GGGCAGTGACGCGACG
Mouse NF- $\kappa$ B -R	AGCGCCCCTCGCATTTATAG
Mouse IFN- $\gamma$ -F	CGGCACAGTCATTGAAAGCCTA
Mouse IFN- $\gamma$ -R	GTTGCTGATGGCCTGATTGTC
Mouse RPLP0 -F	AGATTTCGGGATATGCTGTTGGC
Mouse RPLP0 -R	TCGGGTCCTAGACCAGTGTTT
Mouse IL-6 -F	GAGGATACCACTCCCAACAGACC
Mouse IL-6 -R	AAGTGCATCATCGTTGTTTCATACA

**Supplementary Table 2. miRNA primer details.**

<b>miRNA</b>	<b>QIAGEN catalogue number</b>
hsa-miR-24	MS00006552
hsa-miR-98-5p	MS00003367
hsa-miR-675	MS00032109
hsa-miR-200a-3p	MS00003738
hsa-miR-124-3p	MS00006622